MondegarAI
DAFNA Capital Management LLC

Q3 2025 · 13F-HR

DAFNA Capital Management LLCholdings as filed

Filed 2025-11-14 · accession 0001389933-25-000008

$404.8M
Reported value
75
Positions
2025-09-30
Period end
View analyzed profile →PRO

The Brief · DAFNA Capital Management LLC · Q3 2025

AI · grounded in 13F

DAFNA Capital Management LLC established a new position in Stereotaxis Inc STXS valued at $42.5M. The fund also initiated new stakes in SPDR S&P Biotech ETF XBI for $40.2M and Revolution Medicines Inc RVMD for $30.7M. Other new additions include Cytokinetics Inc CYTK and Atricure Inc ATRC.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
85916J409STXSSTEREOTAXIS INC$42.5M10.5%13,680,554CommonSOLE
78464A870XBISPDR S&P BIOTECH ETF$40.2M9.94%401,505CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$30.7M7.58%657,176CommonSOLE
23282W605CYTKCYTOKINETICS INC$21.7M5.36%394,940CommonSOLE
04963C209ATRCATRICURE INC$20.9M5.16%592,273CommonSOLE
N5749R1002GHMERUS BV$20.8M5.13%220,451CommonSOLE
464287556IBBISHARES NASDAQ BIOTECH INDX$14.8M3.66%102,500CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$14.7M3.63%539,923CommonSOLE
05463X106AXGNAXOGEN INC$13.2M3.27%742,282CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$11.6M2.86%287,939CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$9.9M2.45%70,615CommonSOLE
03969F109RCUSARCUS BIOSCIENCES INC$8.5M2.11%627,626CommonSOLE
87164F105SNDXSYNDAX PHARMACEUTICALS INC$7.7M1.90%500,702CommonSOLE
23954D109DAWNGBXDAY ONE BIOPHARMACEUTICALS I$7.0M1.74%999,163CommonSOLE
04351P101ASNDUSDASCENDIS PHARMA A/S$6.6M1.63%33,177CommonSOLE
04351PAD3ASND 2.25 04/01/28ASCENDIS PHARMA A/S$5.4M1.34%4,000,000CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$5.1M1.27%422,731CommonSOLE
055477103BCAXBICARA THERAPEUTICS INC$5.0M1.24%317,001CommonSOLE
45780L104INGNINOGEN INC$4.9M1.22%605,625CommonSOLE
20451W101CMPSCOMPASS PATHWAYS PLC$4.6M1.15%811,046CommonSOLE
36315X101LKFTGALAPAGOS NV$4.5M1.11%130,175CommonSOLE
252131107DXCMDEXCOM INC$4.4M1.09%65,552CommonSOLE
875372203TNDMTANDEM DIABETES CARE INC$4.3M1.07%355,208CommonSOLE
50127T109KURAKURA ONCOLOGY INC$4.1M1.01%463,368CommonSOLE
G01767105ALKSALKERMES PLC$4.0M1.00%134,748CommonSOLE
86150R107STOKSTOKE THERAPEUTICS INC$4.0M0.99%169,791CommonSOLE
834203309SLNOSOLENO THERAPEUTICS INC$3.6M0.89%53,000CommonSOLE
G1110E107BHVNBIOHAVEN LTD$3.5M0.87%235,235CommonSOLE
28036F105EWTXEDGEWISE THERAPEUTICS INC$3.5M0.86%213,736CommonSOLE
N71542109PRQRPROQR THERAPEUTICS N V$3.3M0.82%1,567,561CommonSOLE
517125100LRMRLARIMAR THERAPEUTICS INC$3.3M0.82%1,027,764CommonSOLE
20454B104CMPXCOMPASS THERAPEUTICS INC$3.3M0.82%946,661CommonSOLE
603170101MLYSMINERALYS THERAPEUTICS INC$3.2M0.78%83,490CommonSOLE
640268306NKTRNEKTAR THERAPEUTICS$3.1M0.77%54,998CommonSOLE
45258J102IMVTIMMUNOVANT INC$3.1M0.76%191,493CommonSOLE
500946108KRROKORRO BIO INC$2.9M0.72%60,804CommonSOLE
03843E104AQSTAQUESTIVE THERAPEUTICS INC$2.9M0.71%512,589CommonSOLE
24823R105DNLIDENALI THERAPEUTICS INC$2.4M0.60%168,500CommonSOLE
52886X107LXEOLEXEO THERAPEUTICS INC$2.4M0.59%358,083CommonSOLE
014442107ALECALECTOR INC$2.4M0.58%798,351CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$2.3M0.58%319,775CommonSOLE
75383L102RAPPRAPPORT THERAPEUTICS INC$2.2M0.55%75,000CommonSOLE
872381108TELATELA BIO INC$2.1M0.53%1,441,029CommonSOLE
45784P101PODDINSULET CORP$2.1M0.52%6,870CommonSOLE
M68830112MDWDMEDIWOUND LTD$2.0M0.51%113,612CommonSOLE
004397105ARAYACCURAY INC$2.0M0.50%1,222,358CommonSOLE
N44445109IMTXIMMATICS NV$2.0M0.49%235,000CommonSOLE
019770106ALLOALLOGENE THERAPEUTICS INC$1.7M0.42%1,380,118CommonSOLE
92686J106VKTXVIKING THERAPEUTICS INC$1.7M0.42%64,516CommonSOLE
09058V103BCRXBIOCRYST PHARMACEUTICALS INC$1.7M0.41%218,255CommonSOLE
86366E106GPCRSTRUCTURE THERAPEUTICS INC$1.7M0.41%59,000CommonSOLE
55287L101MBXMBX BIOSCIENCES INC$1.5M0.37%85,000CommonSOLE
82835W108SPRYARS PHARMACEUTICALS INC$1.4M0.35%140,500CommonSOLE
016255101ALGNALIGN TECHNOLOGY INC$1.4M0.34%11,000CommonSOLE
492327101KROSKEROS THERAPEUTICS INC$1.3M0.32%80,716CommonSOLE
457730109INSPINSPIRE MEDICAL SYSTEMS INC$1.3M0.32%17,200CommonSOLE
68622P109ORICORIC PHARMACEUTICALS INC$1.3M0.31%104,671CommonSOLE
09203E105BDTXBLACK DIAMOND THERAPEUTICS I$1.2M0.29%307,070CommonSOLE
68572M106OBIOORCHESTRA BIOMED HOLDINGS INC$901,8170.22%363,636CommonSOLE
10501L106BWAYBRAINSWAY LTD$858,4780.21%56,966CommonSOLE
15673T100IPSCCENTURY THERAPEUTICS INC$848,7080.21%1,704,232CommonSOLE
29479A108ERASERASCA INC$763,0000.19%350,000CommonSOLE
M8001Q126PYPDPOLYPID LTD$693,3470.17%207,900CommonSOLE
09075V102BNTXBIONTECH SE$690,3400.17%7,000CommonSOLE
15117B202CLDXCELLDEX THERAPEUTICS INC NEW$634,2810.16%24,518CommonSOLE
344174107FHTXFOGHORN THERAPEUTICS INC$620,3410.15%126,859CommonSOLE
M96088105URGNUROGEN PHARMA LTD$548,9240.14%27,515CommonSOLE
64135M105NGNENEUROGENE INC$526,3990.13%30,375CommonSOLE
088786108BCYCBICYCLE THERAPEUTICS PLC$499,1680.12%64,492CommonSOLE
H0036K147ADCTADC THERAPEUTICS SA$488,3240.12%122,081CommonSOLE
M25722105CGENCOMPUGEN LTD$400,4310.10%272,402CommonSOLE
869367102STROSUTRO BIOPHARMA INC$379,5590.09%437,079CommonSOLE
05280R100AUTLAUTOLUS THERAPEUTICS PLC$292,2850.07%179,316CommonSOLE
09090D301PHGEBIOMX INC$210,5960.05%401,136CommonSOLE
03836J201APREAPREA THERAPEUTICS INC$202,3320.05%137,174CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.